Merck & Co., Inc. (NYSE:MRK) Receives Average Rating of “Moderate Buy” from Analysts

Merck & Co., Inc. (NYSE:MRK) has received a consensus recommendation of “Moderate Buy” from the twenty-two ratings firms that are presently covering the firm, Marketbeat.com reports. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $135.50.

A number of equities research analysts have commented on MRK shares. Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. Scotiabank lifted their price objective on shares of Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, June 30th. Morgan Stanley boosted their target price on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. Cantor Fitzgerald restated a “neutral” rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Finally, Wells Fargo & Company lifted their price target on Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 8th.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrade and higher valuations: Daiwa Securities upgraded MRK from “neutral” to “outperform” and set a $143 price target. Other analysts have raised fair-value estimates into the $140–$155 range, citing pipeline progress, business-development activity and late-stage therapies. Daiwa Securities upgrade
• Positive Sentiment: Business momentum remains supportive: MRK recently touched a record high, while Keytruda demand, oncology products, new launches and Animal Health helped drive quarterly revenue of $16.61 billion, above the $16.37 billion consensus estimate. The company also exceeded earnings expectations and reported 5.1% year-over-year revenue growth. Merck fair value and pipeline progress
• Positive Sentiment: Income and diversification appeal: Merck declared its regular $0.85 quarterly dividend, or $3.40 annualized, while potential expansion of ENFLONSIA for RSV prevention could broaden growth beyond oncology.
• Neutral Sentiment: Insider selling warrants monitoring: EVP Chirfi Guindo sold 10,000 shares for $1.35 million, following substantial sales by executives Jennifer Zachary and Richard Deluca. Each executive retained a meaningful stake, so the transactions may reflect personal financial decisions rather than a deteriorating outlook. Merck insider selling report
• Negative Sentiment: Keytruda concentration is a future risk: Patent expiration and increasing competition could pressure Merck’s largest growth driver. Investors will need evidence that the pipeline and newer products can offset eventual Keytruda sales declines. Keytruda growth outlook

Insider Activity

In other Merck & Co., Inc. news, EVP David R. Maraldo sold 18,706 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the transaction, the executive vice president directly owned 18,212 shares in the company, valued at $2,344,248.64. This represents a 50.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Richard R. Deluca sold 11,699 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the sale, the executive vice president directly owned 110,167 shares in the company, valued at approximately $14,501,282.21. The trade was a 9.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 228,238 shares of company stock valued at $29,977,783 over the last 90 days. Insiders own 0.17% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Osbon Capital Management LLC purchased a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at $279,000. LM Advisors LLC purchased a new stake in Merck & Co., Inc. in the second quarter valued at $1,814,000. TrinityBridge Ltd purchased a new stake in Merck & Co., Inc. in the second quarter valued at $446,000. Jupiter Wealth Management LLC acquired a new position in Merck & Co., Inc. in the second quarter valued at $1,773,000. Finally, OVERSEA CHINESE BANKING Corp Ltd acquired a new position in Merck & Co., Inc. in the second quarter valued at $969,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $135.78 on Monday. Merck & Co., Inc. has a 1 year low of $77.58 and a 1 year high of $135.97. The stock has a market capitalization of $334.98 billion, a PE ratio of 108.62, a PEG ratio of 5.86 and a beta of 0.19. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The stock has a 50-day simple moving average of $125.54 and a 200-day simple moving average of $120.03.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same period in the prior year, the firm earned $2.13 earnings per share. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, analysts predict that Merck & Co., Inc. will post 2.77 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.